Captor Therapeutics S.A. Total Assets
Captor Therapeutics S.A. total assets. Based on the latest financial reports, Captor Therapeutics S.A. (CTX) holds total assets worth zł44.54 Million PLN (≈ $12.26 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CTX company net worth for the company's overall valuation and market capitalisation.
Total Assets of Captor Therapeutics S.A. (2017–2024)
Total assets of Captor Therapeutics S.A. from 2017 to 2024. This chart illustrates how Captor Therapeutics S.A.'s total assets have evolved over time, based on quarterly financial data. See CTX stock price for real-time trading data and today's change.
Captor Therapeutics S.A. - Asset Composition Analysis
Captor Therapeutics S.A. Total Assets Breakdown (December 2024)
Captor Therapeutics S.A. total assets breakdown as of December 2024. Captor Therapeutics S.A.'s total assets of zł44.54 Million consist of 89.3% current assets and 10.8% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 44.9% |
| Accounts Receivable | zł38.25 Million | 43.7% |
| Inventory | zł0.00 | 0.0% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł415.00K | 0.5% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Captor Therapeutics S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Captor Therapeutics S.A. (CTX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Captor Therapeutics S.A.'s current assets represent 89.3% of total assets in 2024, an increase from 41.2% in 2017.
- Cash Position: Cash and equivalents constituted 44.9% of total assets in 2024, up from 31.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 43.7% of total assets.
Captor Therapeutics S.A. Competitors by Total Assets
Key competitors of Captor Therapeutics S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Captor Therapeutics S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.13 | 2.65 | 0.66 |
| Quick Ratio | 4.13 | 2.65 | 0.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł28.63 Million | zł34.38 Million | zł-6.76 Million |
Captor Therapeutics S.A. - Advanced Valuation Insights
This section examines the relationship between Captor Therapeutics S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.06 |
| Latest Market Cap to Assets Ratio | 0.87 |
| Asset Growth Rate (YoY) | -10.1% |
| Total Assets | zł87.50 Million |
| Market Capitalization | $75.96 Million USD |
Valuation Analysis
Near Book Valuation: The market values Captor Therapeutics S.A.'s assets close to their book value (0.87x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Captor Therapeutics S.A.'s assets decreased by 10.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Captor Therapeutics S.A. (2017–2024)
The table below shows the annual total assets of Captor Therapeutics S.A. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł87.50 Million ≈ $24.08 Million |
-10.07% |
| 2023-12-31 | zł97.29 Million ≈ $26.78 Million |
-13.90% |
| 2022-12-31 | zł113.00 Million ≈ $31.10 Million |
-21.28% |
| 2021-12-31 | zł143.54 Million ≈ $39.50 Million |
+456.81% |
| 2020-12-31 | zł25.78 Million ≈ $7.09 Million |
+1.90% |
| 2019-12-31 | zł25.30 Million ≈ $6.96 Million |
+40.07% |
| 2018-12-31 | zł18.06 Million ≈ $4.97 Million |
+252.48% |
| 2017-12-31 | zł5.12 Million ≈ $1.41 Million |
-- |
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more